Corpus
Pelvis

Prostate

A walnut-sized gland wrapped around the urethra that produces most of semen — and enlarges in most men with age.

By The Corpus Atlas Editorial TeamUpdated Last reviewed How we source this

About 15–25 g, roughly a walnut

Size in a young adult

Around 20–30%

Share of semen volume

Present in roughly half of men

Benign enlargement by age 60

Around 1 in 8 men

Lifetime prostate cancer diagnosis

Overview

The prostate is a gland the size of a walnut sitting just below the bladder, and its defining anatomical feature is a design flaw: the urethra passes directly through the middle of it. Whatever makes the prostate enlarge therefore squeezes the tube it surrounds, which is why benign prostatic enlargement — a near-universal feature of male ageing — produces urinary rather than sexual symptoms. The gland's actual job is reproductive. It secretes an alkaline, enzyme-rich fluid making up roughly a quarter of semen volume, including prostate-specific antigen, which liquefies semen after ejaculation, and citrate and zinc, which support sperm survival. It also contains muscle that contracts during ejaculation and a valve mechanism that closes the bladder neck to prevent semen entering the bladder. Prostate growth depends on
dihydrotestosteroneA potent androgen made from testosterone within the prostate, driving glandular growth.
, a more potent derivative of testosterone made within the gland itself, which is why the drugs that block its production shrink the prostate. Two distinct conditions dominate prostate medicine and are frequently confused: benign enlargement, which is extremely common and causes symptoms but does not become cancer, and prostate cancer, which typically causes no symptoms at all in its early and most treatable stages. That asymmetry — symptoms from the benign condition, silence from the dangerous one — is the single most important thing to understand about this gland.

Interesting facts

  • The urethra runs directly through the prostate, which is the entire reason a benign gland enlargement causes urinary obstruction.
  • Prostate-specific antigen exists to liquefy semen after ejaculation; its usefulness as a blood test is an accidental by-product of it leaking into circulation.
  • Benign enlargement and prostate cancer arise in different zones — the transition zone around the urethra and the peripheral zone respectively — which is why one causes symptoms and the other usually does not.
  • Prostate cancer is so common in older men that a substantial proportion of men who die of other causes are found to have it at autopsy without ever knowing.
  • The gland concentrates zinc to levels higher than almost any other soft tissue in the body, for reasons still not fully understood.
  • Dihydrotestosterone drives prostate growth, and blocking the enzyme that makes it shrinks the gland by roughly a quarter over several months.

Common misconceptions

  • Benign prostate enlargement leads to prostate cancer.
    They are separate conditions arising in different zones of the gland. Having an enlarged prostate does not increase cancer risk, though both become more common with age so they often coexist.
  • Early prostate cancer causes urinary symptoms.
    It usually causes nothing at all. Urinary symptoms almost always come from benign enlargement. This is precisely why the question of screening exists — symptoms are not a useful early warning.
  • A raised PSA means cancer.
    PSA rises with benign enlargement, infection, inflammation, recent ejaculation, cycling and examination. Most men with a modestly raised PSA do not have cancer, which is why modern practice uses MRI before biopsy.
  • All prostate cancer needs treating.
    Many prostate cancers are so slow-growing they will never cause harm. Active surveillance is now standard for low-risk disease, because treatment carries real risks of incontinence and erectile dysfunction that the cancer may never have justified.
  • Saw palmetto shrinks the prostate.
    Large, well-conducted randomised trials found no benefit over placebo for urinary symptoms, even at high doses. Earlier positive findings came from smaller, weaker studies.
  • Frequent ejaculation causes prostate problems.
    If anything, the observational evidence points modestly the other way — higher ejaculation frequency has been associated with slightly lower prostate cancer risk in large cohort studies.

Anatomy & how it works

A zonal gland encircling the urethra below the bladder, with the clinically important distinction lying in which zone is affected.

  • Transition zone

    Surrounds the urethra and is where benign prostatic hyperplasia develops — hence the urinary obstruction.

  • Peripheral zone

    The largest zone, at the back of the gland, where the majority of prostate cancers arise; palpable on rectal examination.

  • Central zone

    Surrounds the ejaculatory ducts; relatively rarely the site of disease.

  • Prostatic urethra

    The section of urethra passing through the gland, compressed by transition zone enlargement.

  • Glandular acini

    The secretory units producing PSA, citrate, zinc and enzymes that form prostatic fluid.

  • Fibromuscular stroma

    Smooth muscle that contracts during ejaculation and whose tone contributes to urinary obstruction — the target of alpha blocker drugs.

  • Ejaculatory ducts and seminal vesicles

    Deliver sperm and the larger share of seminal fluid through the gland into the urethra.

  • Neurovascular bundles

    The nerves controlling erection running alongside the gland — the structures surgeons attempt to spare during prostatectomy.

Prostatic secretion is continuous and low-level, stored and expelled during ejaculation when the gland's smooth muscle contracts and the bladder neck closes. Growth is hormonally driven: testosterone entering prostate cells is converted by 5-alpha-reductase into
dihydrotestosteroneA potent androgen made from testosterone within the prostate, driving glandular growth.
, which is several times more potent at the androgen receptor. This local amplification explains both why the prostate grows throughout adult life and why blocking that enzyme shrinks it — and, incidentally, why the same drugs treat male pattern hair loss. Urinary obstruction has two components that respond to different drugs: the static component from the physical bulk of tissue, which 5-alpha-reductase inhibitors reduce slowly over months, and the dynamic component from smooth muscle tone, which alpha blockers relieve within days. That distinction is why the two drug classes are often combined. Zone matters diagnostically too — because cancers usually arise in the
peripheral zoneThe rear region of the gland where most prostate cancers arise; palpable on rectal examination.
at the back, they can be felt on rectal examination but cause no urinary symptoms until late.

Primary functions

  • Producing prostatic fluid making up roughly a quarter of semen volume
  • Secreting PSA to liquefy semen and enable sperm motility
  • Contracting during ejaculation to expel semen

Secondary functions

  • Closing the bladder neck during ejaculation to prevent retrograde flow
  • Providing citrate, zinc and enzymes that support sperm survival
  • Buffering the acidity of the vagina to protect sperm
  • Contributing smooth muscle tone to urinary continence

Across a lifetime

Development
The prostate forms under the influence of fetal dihydrotestosterone; 5-alpha-reductase deficiency results in a prostate that never develops normally, an observation that led directly to the drugs used today.
Childhood
The gland remains small and inactive until puberty, when androgens drive it to adult size.
Adulthood
Prostatitis and chronic pelvic pain syndrome are the commonest prostate problems in men under 50, and are frequently mismanaged as recurrent infection when most cases are not bacterial.
Later life
Benign enlargement becomes near-universal, present in roughly half of men by 60 and the large majority by 80. Prostate cancer incidence rises steeply, and most cases are diagnosed after 65.
Sex differences
The prostate exists only in males. The female equivalent, the Skene's glands, produce a similar secretion including PSA but are far smaller and do not surround the urethra.

Body connections

The prostate's health significance is disproportionate to its function. Reproductively it is useful but not individually essential — men live normally without it. Clinically it accounts for an enormous share of male healthcare: benign enlargement affects most ageing men and substantially reduces quality of life through sleep-disrupting nocturia, while prostate cancer is one of the most commonly diagnosed cancers in men. Its position wrapped around the urethra and adjacent to the nerves of erection means that both the diseases and their treatments carry consequences for urination and sexual function, which is why decisions here involve genuine trade-offs rather than obvious answers.

Body connections

How this links to the rest of you

Bladder

The prostate sits directly below the bladder and encircles its outlet, so enlargement obstructs flow and causes the bladder muscle to thicken and become overactive.

Reproductive system

The prostate contributes the majority of non-sperm seminal fluid and its muscle drives ejaculation.

Hips & pelvis

Pelvic floor muscle tension is a major contributor to chronic pelvic pain syndrome, which is frequently misattributed to prostate infection.

Large intestine & gut microbiome

The rectum lies immediately behind the gland, which is what makes rectal examination and transrectal biopsy possible.

Kidneys

Prolonged bladder outlet obstruction can back pressure up to the kidneys and cause renal impairment — the main reason severe obstruction needs treating.

Bones

Prostate cancer characteristically spreads to bone, and hormone therapy for it causes substantial bone density loss requiring monitoring.

Pituitary gland

Pituitary LH drives testicular testosterone production, and prostate cancer hormone therapy works by interrupting this axis.

Nerves & peripheral nervous system

The nerves controlling erection run alongside the prostate, which is why prostate surgery risks erectile dysfunction.

How lifestyle changes it

Exercise

Physical activity is associated with lower risk of both benign enlargement symptoms and aggressive prostate cancer. Prolonged cycling can transiently raise PSA and cause perineal symptoms.

Nutrition

Dietary evidence is largely observational and modest. Diets high in processed meat and low in vegetables are associated with somewhat higher risk; high-dose calcium and possibly high dairy intake have been linked to increased risk in some cohorts.

Hydration

Fluid timing matters practically — reducing evening fluid and caffeine substantially improves nocturia, which is often the most disruptive urinary symptom.

Sleep

Nocturia is the leading cause of disrupted sleep in older men, and the resulting fragmentation contributes to daytime fatigue and falls risk.

Stress

Stress and anxiety are strongly associated with chronic pelvic pain syndrome, where pelvic floor muscle tension and central pain sensitisation are more relevant than any prostate infection.

Ageing

Benign enlargement is essentially universal with age, and prostate cancer incidence rises steeply. Both are age-driven processes rather than lifestyle diseases.

Environment

Obesity is associated with more aggressive prostate cancer and worse surgical outcomes. Smoking is associated with worse prostate cancer outcomes though not clearly with incidence.

Genetics

Family history roughly doubles risk, and more if a relative was diagnosed young. BRCA2 mutations substantially raise risk of aggressive disease. Men of African ancestry have markedly higher incidence and mortality, and often earlier onset.

Symptoms & conditions

Common conditions

Rare conditions

  • Prostatic abscess
  • Prostate sarcoma
  • Granulomatous prostatitis
  • Bladder neck contracture after surgery
  • Prostatic intraepithelial neoplasia

Acute & chronic problems

  • Acute bacterial prostatitis
  • Acute urinary retention
  • Post-biopsy sepsis
  • Haematuria after instrumentation
  • Benign prostatic hyperplasia with lower urinary tract symptoms
  • Chronic prostatitis / chronic pelvic pain syndrome
  • Prostate cancer, from indolent to aggressive
  • Erectile dysfunction and incontinence following treatment
  • Recurrent urinary tract infection secondary to incomplete emptying

Early warning signs

  • Getting up more than once or twice a night to urinate
  • A weaker stream, or hesitancy before flow starts
  • Feeling the bladder has not emptied completely
  • Increasing urgency and frequency during the day
  • Dribbling at the end of urination
  • Needing to strain to start

Risk factors

  • Increasing age, the dominant factor for both conditions
  • Family history of prostate cancer, especially at a young age
  • African ancestry, with markedly higher incidence and mortality
  • BRCA2 and other inherited mutations
  • Obesity, associated with more aggressive disease
  • Diets high in processed meat and low in vegetables

Protective factors

  • Regular physical activity
  • Maintaining a healthy body weight
  • Informed discussion of PSA testing rather than either routine testing or routine avoidance
  • MRI before biopsy, which reduces unnecessary biopsies and overdiagnosis
  • Active surveillance for low-risk cancer, avoiding treatment harms
  • Reducing evening fluid and caffeine for nocturia

Optimise & recover

Prevention

  • Stay physically active and maintain a healthy weight — both are associated with lower risk of aggressive disease and fewer urinary symptoms
  • Have an informed conversation about PSA testing from around 50, or 45 with a family history or African ancestry; the right answer depends on your values, not just the numbers
  • Do not rely on urinary symptoms as a cancer warning — early prostate cancer is silent, and symptoms almost always mean benign enlargement
  • If you are offered a biopsy, ask whether an MRI has been done first; MRI-first pathways reduce unnecessary biopsies substantially
  • Reduce evening fluid, caffeine and alcohol to improve nocturia, which is usually the most disruptive symptom
  • Do not spend money on saw palmetto — the largest good-quality trials found no benefit over placebo

Recovery

  • Pelvic floor muscle training started before prostate surgery and continued afterwards speeds return of urinary continence
  • Expect continence to improve over several months after prostatectomy rather than immediately; most men improve substantially by twelve months
  • Erectile recovery after nerve-sparing surgery takes up to two years, and early use of PDE5 inhibitors may support it
  • For chronic pelvic pain syndrome, repeated antibiotic courses rarely help; pelvic floor physiotherapy and a multimodal approach do better
  • On hormone therapy, resistance and weight-bearing exercise directly counter the muscle and bone loss it causes

Pelvic floor rehabilitation is the central intervention after prostate surgery, and the evidence favours starting it before the operation rather than after — pre-operative training accelerates the return of continence. Programmes progress from isolated pelvic floor contractions to coordination with breathing and functional loading, ideally supervised by a specialist physiotherapist, since a large proportion of men perform the contraction incorrectly without feedback. For chronic pelvic pain syndrome the emphasis is quite different: much of the pain relates to pelvic floor muscle overactivity and central sensitisation rather than infection, so treatment involves downtraining an overactive floor, addressing pain mechanisms and avoiding the cycle of repeated antibiotic courses that characterises poor management of this condition.

Movement library

  • Pelvic floor relaxation (downtraining)

    For chronic pelvic pain with an overactive floor, learning to release rather than contract is the priority.

    Beginner
  • Hip and pelvic mobility work

    Reduces the muscular tension around the pelvis that contributes to chronic pelvic pain.

    Beginner
  • Diaphragmatic breathing with pelvic floor coordination

    Links breathing to pelvic floor function, useful in both continence training and pain management.

    Beginner
  • Pelvic floor muscle training

    Started before prostate surgery and continued afterwards; the best-evidenced intervention for post-prostatectomy continence.

    Beginner
  • Progressive resistance training

    Directly counters the muscle loss caused by androgen deprivation therapy, with good trial support.

    Beginner
  • Weight-bearing and impact exercise

    Protects bone density, which falls substantially on hormone therapy for prostate cancer.

    Beginner
  • Aerobic exercise

    Reduces fatigue during and after prostate cancer treatment and supports general cardiovascular health.

    Beginner
  • Bladder training and timed voiding

    Reduces urgency and frequency in benign enlargement alongside medication.

    Beginner
  • Hip flexor and adductor stretching

    Eases the muscular tension around the pelvis associated with chronic pelvic pain.

    Beginner
  • Gentle piriformis and gluteal stretching

    Addresses deep pelvic muscular contributors to perineal and pelvic discomfort.

    Beginner

Internal pelvic floor manual therapy delivered by a specialist physiotherapist has reasonable evidence in chronic pelvic pain syndrome with an overactive floor. Prostate massage as a general wellness practice has no evidence base, and vigorous massage should be avoided in acute bacterial prostatitis, where it can spread infection. Note that any prostate manipulation raises PSA temporarily.

Habits worth building

  • Stop drinking fluid two to three hours before bed if nocturia is disrupting your sleep
  • Take your time and avoid straining when urinating; double voiding a minute later can help empty more completely
  • Avoid ejaculation, vigorous cycling and prostate examination in the 48 hours before a PSA test, since all can raise it

Nutrition, devices & products

Prostate nutrition is an area where the marketing considerably exceeds the evidence. Large randomised trials have been notably disappointing: saw palmetto failed to beat placebo for urinary symptoms even at triple doses, and the SELECT trial of selenium and vitamin E not only failed to prevent prostate cancer but found vitamin E increased incidence. Lycopene and green tea have observational support and no convincing trial evidence. What the evidence does support is unglamorous — a dietary pattern high in vegetables and low in processed meat, maintaining a healthy weight, and adjusting fluid timing to manage nocturia. Very high calcium intake and possibly high dairy consumption have been associated with increased risk in some cohorts, which argues against high-dose calcium supplementation without a bone indication.

Foods to prioritise

  • Vegetables and fruit, particularly cruciferous vegetables and tomato products
  • Oily fish for omega-3 fats
  • A dietary pattern supporting healthy body weight
  • Adequate fluid earlier in the day, tapering in the evening for nocturia
  • Adequate protein and calcium if on hormone therapy, for muscle and bone

Foods to limit

  • Processed and charred red meat, associated with higher risk in cohort studies
  • Caffeine and alcohol in the evening, which worsen urinary frequency and urgency
  • Very high calcium supplementation without a specific bone indication
  • Excess energy intake, since obesity is linked to more aggressive disease
SupplementEvidenceNote
Saw palmettoLimitedThe largest, best-designed randomised trials found no benefit over placebo for urinary symptoms, even at doses up to three times standard.
Vitamin E and seleniumLimitedThe SELECT trial found no prevention benefit, and vitamin E supplementation significantly increased prostate cancer incidence — an important cautionary result.
LycopeneEmergingObservational data suggest an association with lower risk; intervention trials have not confirmed a benefit.
ZincLimitedThe prostate concentrates zinc, but high-dose supplementation has been associated with increased advanced prostate cancer risk in at least one large cohort.
Pygeum and beta-sitosterolLimitedSome small positive studies of poor methodological quality; not supported by robust trials.

Devices & wearables

  • Bladder scanners to measure post-void residual volume
  • Intermittent and indwelling catheters for retention
  • Continence pads and penile clamps during post-surgical recovery
  • Vacuum erection devices for post-treatment erectile dysfunction
  • Biofeedback devices for pelvic floor training
  • No prostate-specific wearable; activity trackers support the exercise that matters during and after treatment

Professional treatments

  • PSA blood testing with informed discussion of benefits and harms
  • Digital rectal examination
  • Multiparametric MRI before biopsy, now standard practice
  • Transperineal or transrectal targeted biopsy
  • Active surveillance protocols for low-risk cancer
  • TURP, laser enucleation and newer minimally invasive treatments for benign enlargement
  • Radical prostatectomy and radiotherapy for localised cancer
  • Specialist pelvic health physiotherapy

Educational mention only, not a recommendation: Alpha blockers such as tamsulosin, relieving smooth muscle tone within days, 5-alpha-reductase inhibitors such as finasteride and dutasteride, shrinking the gland over months and lowering PSA by about half, Combination therapy for larger glands, Tadalafil, which improves both urinary symptoms and erectile function, Antibiotics for genuine bacterial prostatitis, though not for most chronic pelvic pain, Androgen deprivation therapy for advanced prostate cancer, Newer androgen receptor pathway inhibitors for advanced disease.

When to seek medical care

Urinary symptoms are worth discussing because they are treatable and because they affect sleep and quality of life substantially — but they are not a cancer screening test, since early prostate cancer is silent. If you are considering PSA testing, ask for a proper discussion of what a raised result would lead to, because the harms of overdiagnosis are real and so is the benefit in reducing advanced disease. Complete inability to pass urine with a painful bladder is an emergency. Fever with rigors and pelvic pain, particularly within days of a biopsy, needs urgent assessment for sepsis. New back pain with leg weakness in a man with known prostate cancer may indicate spinal cord compression and requires immediate attention.

Seek care promptly if you notice

  • Complete inability to pass urine with a painful, full bladder
  • Fever with shivering and pelvic or perineal pain
  • Fever or feeling very unwell within days of a prostate biopsy
  • New back pain with leg weakness, numbness or bladder changes in known prostate cancer
  • Visible blood in the urine, particularly with clots
  • Bone pain with unexplained weight loss
  • Rapidly worsening urinary stream with reduced volumes

Research & frequently asked questions

Current research

  • MRI-first diagnostic pathways have substantially changed practice, allowing many men to avoid biopsy altogether and reducing detection of clinically insignificant cancers — one of the clearest recent improvements in cancer diagnostics.
    1

    New England Journal of Medicine · 2023

    Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

    The ProtecT randomised trial found very low and statistically similar prostate cancer mortality across all three arms at 15 years, with treatments differing mainly in urinary and sexual side effects.

  • Long-term follow-up of the ProtecT trial has shown that for localised prostate cancer, active monitoring, surgery and radiotherapy produce very similar mortality at 15 years, with treatment differing mainly in side effects — a finding that has reshaped shared decision-making.
    2

    New England Journal of Medicine · 2018

    MRI-Targeted or Standard Biopsy for Prostate Cancer Diagnosis

    The PRECISION trial showed MRI-targeted biopsy detected more clinically significant cancers and fewer insignificant ones than standard systematic biopsy, while allowing some men to avoid biopsy entirely.

Emerging therapies

  • PSMA PET imaging, markedly more sensitive for detecting spread than conventional scans
  • Focal therapy including HIFU and cryotherapy, treating part of the gland to reduce side effects
  • Genomic tests to distinguish indolent from aggressive disease at diagnosis
  • Minimally invasive treatments for benign enlargement such as prostatic urethral lift and water vapour therapy
  • PARP inhibitors for men with BRCA and related mutations

Scientific controversies

  • PSA screening remains genuinely contested: it reduces prostate cancer mortality modestly but causes substantial overdiagnosis and overtreatment, which is why guidelines emphasise informed individual choice rather than population screening.
  • How much treatment low-risk prostate cancer needs continues to be debated, though the ProtecT results have strengthened the case for active monitoring considerably.
  • The commercial supplement market for prostate health persists despite consistently negative high-quality trials, and the SELECT trial finding that vitamin E increased cancer incidence is a reminder that supplementation is not risk-free.

PSA was introduced as a monitoring test for men already diagnosed with prostate cancer, then adopted for screening — a use it was never validated for, which produced a dramatic rise in diagnoses without an equivalent fall in deaths. The resulting decades-long argument about overdiagnosis is one of the defining debates in modern cancer medicine. The observation that men with congenital 5-alpha-reductase deficiency have underdeveloped prostates led directly to finasteride, an unusually clean example of a rare genetic condition generating a widely used drug. The ProtecT trial, reporting long-term outcomes in 2023, provided the randomised evidence the field had lacked for forty years.

Frequently asked questions

Does an enlarged prostate mean I will get prostate cancer?

No. They are separate conditions arising in different parts of the gland — benign enlargement in the transition zone around the urethra, cancer usually in the peripheral zone at the back. An enlarged prostate does not raise your cancer risk, though both become more common with age.

Should I have a PSA test?

It depends on your values, and it deserves a proper conversation. PSA testing modestly reduces prostate cancer deaths but also leads to diagnosing cancers that would never have caused harm, with real risks from treatment. Family history and African ancestry shift the balance toward testing, and earlier.

What does a raised PSA actually mean?

Often not cancer. It rises with benign enlargement, infection, inflammation, recent ejaculation, cycling and rectal examination. That is why modern practice does an MRI before deciding on a biopsy — it lets many men avoid biopsy entirely.

Does saw palmetto help urinary symptoms?

The best evidence says no. Large, well-designed randomised trials found no benefit over placebo even at three times the usual dose. The earlier positive results came from smaller and methodologically weaker studies.

Can prostate cancer be left untreated?

Low-risk disease often can, and increasingly is. Active surveillance monitors it with regular tests and scans, treating only if it progresses. The ProtecT trial found very similar survival at 15 years between monitoring, surgery and radiotherapy — the differences were mainly in side effects.

Why do I need to urinate so much at night?

Nocturia in older men usually reflects benign prostate enlargement plus age-related changes in how the kidneys handle fluid overnight. Reducing evening fluid, caffeine and alcohol helps, and medication is effective. It is worth treating, because the sleep disruption has real consequences.

Will prostate treatment affect my sex life?

It can, and this is central to the decision. The nerves controlling erection run alongside the gland, so surgery and radiotherapy both carry erectile dysfunction risk, and surgery carries incontinence risk. These trade-offs are why treatment choice depends so much on what matters to you.

Is chronic prostatitis an infection?

Usually not. Most chronic prostatitis is chronic pelvic pain syndrome, in which pelvic floor muscle overactivity and pain sensitisation matter more than bacteria. Repeated antibiotic courses rarely help; pelvic floor physiotherapy and a broader approach do better.

Explore further

Glossary

Benign prostatic hyperplasia
Non-cancerous enlargement of the prostate's transition zone, compressing the urethra and causing urinary symptoms.
PSA
Prostate-specific antigen, an enzyme that liquefies semen; its blood level is used to assess prostate disease but is not cancer-specific.
Dihydrotestosterone
A potent androgen made from testosterone within the prostate, driving glandular growth.
Transition zone
The region around the urethra where benign enlargement develops.
Peripheral zone
The rear region of the gland where most prostate cancers arise; palpable on rectal examination.
Active surveillance
Monitoring low-risk prostate cancer with regular testing rather than treating immediately.
Nocturia
Waking at night to urinate; often the most disruptive symptom of prostate enlargement.
Chronic pelvic pain syndrome
Persistent pelvic pain, usually without infection, in which pelvic floor overactivity is a major factor.
Androgen deprivation therapy
Treatment reducing testosterone to slow advanced prostate cancer, with muscle and bone loss as side effects.

Trusted organisations & further reading

Medical disclaimer

This page is for general education and does not replace personalised medical advice. If you have concerning symptoms, or before starting a new supplement, medication or exercise programme, speak with a qualified healthcare professional.